Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Ehab L. Atallah MD

Ehab L. Atallah MD profile photo picture

Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

Member of the Cancer Center
Member of the Center for Immunology

View Curriculum Vitae

Research Areas of Interest

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Azacitidine
  • Hematologic Neoplasms
  • Imatinib Mesylate
  • Janus Kinase 2
  • Janus Kinases
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid, Chronic-Phase
  • Leukemia, Promyelocytic, Acute
  • Molecular Targeted Therapy
  • Myelodysplastic Syndromes
  • Myeloproliferative Disorders
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Primary Myelofibrosis
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • Treatment Outcome
  • Young Adult

    • Leadership Positions

  • Associate Director of the Cancer Service Line

    • Publications (123)

  • Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) (Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SdCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR) Blood Cancer Journal December 2024;14(1) SCOPUS ID: 2-s2.0-85185454442 12/01/2024    
  • Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry. (Muthiah C, Narra R, Atallah E, Juan W, Szabo A, Guru Murthy GS) Leuk Res 2024 May;140:107496 PMID: 38547577 SCOPUS ID: 2-s2.0-85188991221 03/29/2024    
  • Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). (Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR) Blood Cancer J 2024 Feb 20;14(1):32 PMID: 38378617 PMCID: PMC10879201 SCOPUS ID: 2-s2.0-85185454442 02/21/2024    
  • Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers. (Abaza Y, Winer ES, Murthy GSG, Shallis RM, Matthews AH, Badar T, Geramita EM, Kota VK, Swaroop A, Doukas P, Bradshaw D, Helenowski IB, Liu Y, Zhang H, Im A, Litzow MR, Perl AE, Atallah E, Altman JK) Am J Hematol 2024 Apr;99(4):606-614 PMID: 38342997 SCOPUS ID: 2-s2.0-85185125850 02/12/2024    
  • Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. (Winn AN, Atallah E, Cortes J, Deininger MWN, Kota V, Larson RA, Moore JO, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Shah NP, Thompson JE, Flynn KE) JAMA Netw Open 2023 Dec 01;6(12):e2347950 PMID: 38109114 PMCID: PMC10728762 SCOPUS ID: 2-s2.0-85180310408 12/18/2023       1 Citation
  • Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review. (Atallah E, Saini L, Maegawa R, Rajput T, Corbin R, Viana R) Ther Adv Hematol 2023;14:20406207221150305 PMID: 38105770 PMCID: PMC10725100 SCOPUS ID: 2-s2.0-85179719949 12/18/2023    
  • Eligibility criteria: too big, too small or just right? (Atallah E) Haematologica 2024 Apr 01;109(4):1021 PMID: 37822257 PMCID: PMC10985446 SCOPUS ID: 2-s2.0-85189747909 10/12/2023    
  • Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia (Rezazadeh A, Deininger M, Atallah E) Current Treatment Options in Oncology August 2023;24(8):1036-1051 SCOPUS ID: 2-s2.0-85161400330 08/01/2023    
  • Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy. (Taylor S, Murthy GSG, Runaas L, Michaelis LC, Carlson K, Atallah EL, Abedin SM) Leuk Res 2023 Sep;132:107348 PMID: 37423073 SCOPUS ID: 2-s2.0-85164434355 07/10/2023    
  • Real-world Management of CML: Outcomes and Treatment Patterns. (Held N, Atallah EL) Curr Hematol Malig Rep 2023 Oct;18(5):167-175 PMID: 37395944 SCOPUS ID: 2-s2.0-85163857366 07/03/2023    
  • Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia. (Guru Murthy GS, Atallah E) Hematol Oncol Stem Cell Ther 2023 May 23;16(4):346-350 PMID: 37363977 SCOPUS ID: 2-s2.0-85163318224 06/26/2023    
  • Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia. (Rezazadeh A, Deininger M, Atallah E) Curr Treat Options Oncol 2023 Aug;24(8):1036-1051 PMID: 37300657 SCOPUS ID: 2-s2.0-85161400330 06/10/2023    
  • Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. (Zarnegar-Lumley S, Alonzo TA, Gerbing RB, Othus M, Sun Z, Ries RE, Wang J, Leonti A, Kutny MA, Ostronoff F, Radich JP, Appelbaum FR, Pogosova-Agadjanyan EL, O'Dwyer K, Tallman MS, Litzow M, Atallah E, Cooper TM, Aplenc RA, Abdel-Wahab O, Gamis AS, Luger S, Erba H, Levine R, Kolb EA, Stirewalt DL, Meshinchi S, Tarlock K) Blood Adv 2023 Oct 10;7(19):5941-5953 PMID: 37267439 PMCID: PMC10562769 SCOPUS ID: 2-s2.0-85174324824 06/02/2023       5 Citations
  • SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML). (Mikhaeel S, Atallah E) Clin Lymphoma Myeloma Leuk 2023 May;23(5):333-339 PMID: 36934065 SCOPUS ID: 2-s2.0-85150380400 03/19/2023    
  • Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). (Badar T, Atallah E, Shallis R, Saliba AN, Patel A, Bewersdorf JP, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg AD, Abaza Y, Murthy GSG, Kota V, Litzow MR) Leukemia 2023 Apr;37(4):799-806 PMID: 36807649 SCOPUS ID: 2-s2.0-85148365155 02/23/2023       11 Citations
  • A Survey of Patient Experience in CML: American and Canadian Perspectives. (Hillis C, Flynn KE, Goldman EH, Moreira-Lucas TS, Visentini J, Dorman S, Ballinger R, Byrnes HF, De Palma A, Barbier V, Machado L, Atallah E) Patient Prefer Adherence 2023;17:331-347 PMID: 36760231 PMCID: PMC9904222 SCOPUS ID: 2-s2.0-85147714122 02/11/2023    
  • Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. (Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D) J Cancer Res Clin Oncol 2023 Aug;149(9):6247-6262 PMID: 36707445 PMCID: PMC10356870 SCOPUS ID: 2-s2.0-85146935763 01/28/2023       5 Citations
  • Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review (Atallah E, Saini L, Maegawa R, Rajput T, Corbin R, Viana R) Therapeutic Advances in Hematology January-December 2023;14 SCOPUS ID: 2-s2.0-85179719949 01/01/2023    
  • Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. (Badar T, Litzow MR, Shallis RM, Patel A, Saliba AN, Burkart M, Bewersdorf JP, Stahl M, De Camargo Correia GS, Guru Murthy GS, Abaza Y, Duvall A, Bradshaw D, Kota V, Dinner S, Goldberg AD, Palmisiano N, Al Kali A, Atallah E) Cancer 2023 Mar 15;129(6):934-945 PMID: 36545710 SCOPUS ID: 2-s2.0-85144909890 12/23/2022       2 Citations
  • Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. (Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Maeda Y, Hosono N, Onozawa M, Kato T, Kim HJ, Hasabou N, Nuthethi R, Tiu R, Levis MJ) Transplant Cell Ther 2023 Apr;29(4):265.e1-265.e10 PMID: 36526260 PMCID: PMC10189888 SCOPUS ID: 2-s2.0-85146459526 12/17/2022       10 Citations
  • Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. (DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, Bejanyan N, Atallah E, Tamari R, Solh MM, Percival ME, de Lima M, Scott B, Oran B, Garcia-Manero G, Hamadani M, Carpenter P, DeZern AE) Transplant Cell Ther 2023 Feb;29(2):71-81 PMID: 36436780 SCOPUS ID: 2-s2.0-85145302399 11/28/2022       13 Citations
  • Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia. (Abedin SM, Badar T, Gauger K, Michaelis LC, Runaas L, Carlson KS, Murthy GG, Atallah E) Leuk Res 2022 Dec;123:106984 PMID: 36401944 SCOPUS ID: 2-s2.0-85141943453 11/20/2022       2 Citations
  • Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. (Advani AS, Moseley A, O'Dwyer KM, Wood BL, Park J, Wieduwilt M, Jeyakumar D, Yaghmour G, Atallah EL, Gerds AT, O'Brien SM, Liesveld JL, Othus M, Litzow M, Stone RM, Sharon E, Erba HP) Blood Adv 2023 Apr 11;7(7):1279-1285 PMID: 36322825 PMCID: PMC10090098 SCOPUS ID: 2-s2.0-85153621947 11/03/2022       10 Citations
  • CML-433 ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI). (Sasaki K, Mauro MJ, Levy MY, Atallah EL, Koller P, Maegawa R, Damon A, Kumar J, Khan M, Cortes JE) Clin Lymphoma Myeloma Leuk 2022 Oct;22 Suppl 2:S299 PMID: 36163933 SCOPUS ID: 2-s2.0-85138139005 09/28/2022    
  • Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective. (Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A) J Health Econ Outcomes Res 2022;9(2):30-36 PMID: 35979529 PMCID: PMC9353133 08/19/2022    
  • Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States. (Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P) J Health Econ Outcomes Res 2022;9(2):19-29 PMID: 35979528 PMCID: PMC9352872 08/19/2022    
  • A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm. (Dong A, Pan X, Lin CW, Huang YW, Krause H, Pan P, Baim A, Thomas MJ, Chen X, Yu J, Michaelis L, Liu P, Wang LS, Atallah E) J Cancer Prev 2022 Jun 30;27(2):129-138 PMID: 35864858 PMCID: PMC9271408 07/23/2022    
  • Low-intensity induction in acute myeloid leukemia. Always in the patients' best interest? (Atallah E) Haematologica 2023 Apr 01;108(4):949-950 PMID: 35861019 PMCID: PMC10071108 SCOPUS ID: 2-s2.0-85151574213 07/22/2022    
  • Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice. (Pettit K, Rezazadeh A, Atallah EL, Radich J) Am Soc Clin Oncol Educ Book 2022 Apr;42:1-19 PMID: 35658498 06/07/2022    
  • Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome. (Corrao K, Rezwan S, Atallah E, Michaelis LC, Runaas L, Harrington AM, Abedin S) Leuk Res Rep 2022;17:100329 PMID: 35651540 PMCID: PMC9150024 SCOPUS ID: 2-s2.0-85131561638 06/03/2022       1 Citation
  • Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults: Progress and Challenges. (Guru Murthy GS, Atallah E) JCO Oncol Pract 2022 Jul;18(7):489-490 PMID: 35588183 SCOPUS ID: 2-s2.0-85132353059 05/20/2022       1 Citation
  • Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. (Flynn KE, Atallah E, Lin L, Shah NP, Silver RT, Larson RA, Panilla-Ibarz J, Thompson JE, Oehler VG, Radich JP, Kota V, Mauro MJ, Schiffer CA, Cortes J, Weinfurt KP) Haematologica 2022 Nov 01;107(11):2641-2649 PMID: 35511672 PMCID: PMC9614525 SCOPUS ID: 2-s2.0-85141308026 05/06/2022       5 Citations
  • Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. (Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, Stahl M, Liu Y, Dinner S, Palmisiano N, Litzow MR, Foran JM) Am J Hematol 2022 Jul;97(7):E232-E235 PMID: 35338673 SCOPUS ID: 2-s2.0-85127372897 03/27/2022       24 Citations
  • Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. (Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Récher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ) Blood 2022 Jun 09;139(23):3366-3375 PMID: 35081255 PMCID: PMC9197557 SCOPUS ID: 2-s2.0-85129375801 01/27/2022       59 Citations
  • Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective (Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A) Journal of Health Economics and Outcomes Research 2022;9(2):30-36 SCOPUS ID: 2-s2.0-85136987579 01/01/2022       1 Citation
  • Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States (Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P) Journal of Health Economics and Outcomes Research 2022;9(2):19-29 SCOPUS ID: 2-s2.0-85136948288 01/01/2022       1 Citation
  • Targeting TIM-3 as a new strategy in immunotherapy: focus on sabatolimab (Murthy GSG, Atallah E) Drugs of the Future November 2021;46(11):901-905 SCOPUS ID: 2-s2.0-85128303136 11/01/2021       1 Citation
  • Treatment-Free Remission: the New Goal in CML Therapy. (Atallah E, Sweet K) Curr Hematol Malig Rep 2021 Oct;16(5):433-439 PMID: 34618317 PMCID: PMC8495665 SCOPUS ID: 2-s2.0-85116717959 10/08/2021       18 Citations
  • Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. (Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE) J Natl Cancer Inst 2022 Jan 11;114(1):160-164 PMID: 34491344 PMCID: PMC8755495 SCOPUS ID: 2-s2.0-85123645552 09/08/2021       10 Citations
  • Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data (Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E) Bone Marrow Transplantation August 2021;56(8):1998-2004 SCOPUS ID: 2-s2.0-85103674051 08/01/2021       10 Citations
  • Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes? (Badar T, Atallah E) Expert Opin Investig Drugs 2021 Jun;30(6):665-673 PMID: 33836635 SCOPUS ID: 2-s2.0-85104939879 04/11/2021       2 Citations
  • Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. (Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E) Bone Marrow Transplant 2021 Aug;56(8):1998-2004 PMID: 33824440 SCOPUS ID: 2-s2.0-85103674051 04/08/2021       10 Citations
  • Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making. (Atallah EL) Best Pract Res Clin Haematol 2021 Mar;34(1):101240 PMID: 33762095 SCOPUS ID: 2-s2.0-85100148584 03/26/2021    
  • Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates. (Atallah EL, Sadek I, Maegawa R, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, Guerin A, Kota V) Leuk Lymphoma 2021 Jul;62(7):1730-1739 PMID: 33648418 SCOPUS ID: 2-s2.0-85110241807 03/03/2021       4 Citations
  • Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making (Atallah EL) Best Practice and Research: Clinical Haematology March 2021;34(1) SCOPUS ID: 2-s2.0-85100148584 03/01/2021    
  • Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. (Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E) Cancer 2021 Apr 01;127(7):1039-1048 PMID: 33259056 SCOPUS ID: 2-s2.0-85096971225 12/02/2020       17 Citations
  • Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. (Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE) JAMA Oncol 2021 Jan 01;7(1):42-50 PMID: 33180106 PMCID: PMC7662490 SCOPUS ID: 2-s2.0-85096163350 11/13/2020       50 Citations
  • Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? (Atallah E, Schiffer CA) Haematologica 2020 Dec 01;105(12):2738-2745 PMID: 33054106 PMCID: PMC7716356 SCOPUS ID: 2-s2.0-85093538868 10/16/2020    
  • Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. (Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, Atallah EL, Guru Murthy GS) Leuk Lymphoma 2021 Jan;62(1):158-166 PMID: 32951486 SCOPUS ID: 2-s2.0-85091139710 09/22/2020       10 Citations
  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study (Goldberg AD, Atallah E, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M) Leukemia Research August 2020;95 SCOPUS ID: 2-s2.0-85085967271 08/01/2020       25 Citations
  • Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase—A real world study (George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L) Leukemia Research July 2020;94 SCOPUS ID: 2-s2.0-85084755644 07/01/2020       4 Citations
  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. (Goldberg AD, Atallah E, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M) Leuk Res 2020 Aug;95:106385 PMID: 32521310 SCOPUS ID: 2-s2.0-85085967271 06/11/2020       25 Citations
  • Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. (Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, Litzow MR, Atallah E) Blood Adv 2020 May 26;4(10):2308-2316 PMID: 32453836 PMCID: PMC7252553 SCOPUS ID: 2-s2.0-85086878601 05/27/2020       27 Citations
  • Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study. (George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L) Leuk Res 2020 Jul;94:106368 PMID: 32442786 SCOPUS ID: 2-s2.0-85084755644 05/23/2020       4 Citations
  • Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. (Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, Aldoss I, Schultz E, Hefazi M, Litzow MR, Kuo E, Wang A, Curran E, Shallis RM, Podoltsev N, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, Advani A, Atallah E) Clin Lymphoma Myeloma Leuk 2020 Aug;20(8):556-560.e2 PMID: 32291234 SCOPUS ID: 2-s2.0-85083004098 04/16/2020       13 Citations
  • Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database. (Guru Murthy GS, Szabo A, Michaelis L, Carlson KS, Runaas L, Abedin S, Atallah E) J Natl Compr Canc Netw 2020 Feb;18(2):169-175 PMID: 32023530 SCOPUS ID: 2-s2.0-85079065513 02/06/2020       20 Citations
  • Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. (Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJ) Blood Adv 2020 Feb 11;4(3):449-457 PMID: 32012214 PMCID: PMC7013258 SCOPUS ID: 2-s2.0-85082200332 02/06/2020       36 Citations
  • In Reply. (Flynn KE, Vanness DJ, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E) Oncologist 2020 Apr;25(4):e744-e745 PMID: 31873972 PMCID: PMC7160403 SCOPUS ID: 2-s2.0-85076804489 12/25/2019    
  • Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. (Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JD) JAMA Oncol 2020 Apr 01;6(4):486-493 PMID: 31830234 PMCID: PMC6990739 SCOPUS ID: 2-s2.0-85076620276 12/13/2019       39 Citations
  • Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation. (Kota V, Atallah E) Clin Lymphoma Myeloma Leuk 2019 Aug;19(8):480-487 PMID: 31171474 SCOPUS ID: 2-s2.0-85066428575 06/07/2019       11 Citations
  • Patients' perspectives on the definition of cure in chronic myeloid leukemia. (Flynn KE, Mauro MJ, George G, Hinman A, Baim A, Kota V, Larson RA, Lipton JH, Thompson JE, Wadleigh M, Atallah E) Leuk Res 2019 May;80:40-42 PMID: 30955853 SCOPUS ID: 2-s2.0-85063942202 04/09/2019       4 Citations
  • Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. (Flynn KE, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E) Oncologist 2019 Sep;24(9):1253-1258 PMID: 30944185 PMCID: PMC6738285 SCOPUS ID: 2-s2.0-85063940883 04/05/2019       15 Citations
  • Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. (Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E) Blood Adv 2019 Feb 26;3(4):508-518 PMID: 30760466 PMCID: PMC6391673 SCOPUS ID: 2-s2.0-85061620083 02/15/2019       61 Citations
  • Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective. (Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL) Leuk Lymphoma 2019 Jun;60(6):1476-1484 PMID: 30668234 SCOPUS ID: 2-s2.0-85060599029 01/23/2019       4 Citations
  • Treatment-Free Remission in CML: the US Perspective. (Guru Murthy GS, Atallah E) Curr Hematol Malig Rep 2019 Feb;14(1):56-61 PMID: 30645715 SCOPUS ID: 2-s2.0-85060169494 01/16/2019       11 Citations
  • Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. (Guru Murthy GS, Pondaiah SK, Abedin S, Atallah E) Leuk Lymphoma 2019 May;60(5):1171-1178 PMID: 30407885 SCOPUS ID: 2-s2.0-85057299329 11/09/2018       25 Citations
  • Incorporating newer agents in the treatment of acute myeloid leukemia. (Raj RV, Abedin SM, Atallah E) Leuk Res 2018 Nov;74:113-120 PMID: 30401522 SCOPUS ID: 2-s2.0-85055577100 11/08/2018       9 Citations
  • Implementation and evaluation of high-dose methotrexate administration guidelines. (Nowak TJ, Lorge AH, Rein LE, Canadeo AM, Frank JP, Samanas LC, Urmanski AM, Atallah EL) J Oncol Pharm Pract 2019 Oct;25(7):1675-1681 PMID: 30360674 SCOPUS ID: 2-s2.0-85059348123 10/27/2018       2 Citations
  • Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. (Guru Murthy GS, Pemmaraju N, Atallah E) Leuk Res 2018 Oct;73:21-23 PMID: 30189324 SCOPUS ID: 2-s2.0-85052637608 09/07/2018       68 Citations
  • Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy. (Voshtina E, Huang H, Raj R, Atallah E) Case Rep Hematol 2018;2018:6514604 PMID: 30155323 PMCID: PMC6092972 08/30/2018    
  • Incidence and survival of therapy related myeloid neoplasm in United States. (Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E) Leuk Res 2018 Aug;71:95-99 PMID: 30048839 SCOPUS ID: 2-s2.0-85050226100 07/27/2018       23 Citations
  • Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. (Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE) BMC Cancer 2018 Apr 02;18(1):359 PMID: 29609532 PMCID: PMC5879565 SCOPUS ID: 2-s2.0-85044841612 04/04/2018       16 Citations
  • Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy. (Schneidewend R, Hosking P, Brazauskas R, Peterson J, Beaudin C, Michaelis L, Atallah E, Hari P, Carlson K) Acta Haematol 2018;139(3):171-175 PMID: 29597188 PMCID: PMC6388419 SCOPUS ID: 2-s2.0-85045039013 03/30/2018    
  • Dasatinib dose management for the treatment of chronic myeloid leukemia. (Talpaz M, Saglio G, Atallah E, Rousselot P) Cancer 2018 Apr 15;124(8):1660-1672 PMID: 29370463 PMCID: PMC5901015 SCOPUS ID: 2-s2.0-85045130913 01/26/2018       18 Citations
  • Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future? (Atallah E, Ritchie E) Expert Opin Pharmacother 2018 Feb;19(2):79-81 PMID: 29308683 SCOPUS ID: 2-s2.0-85041333482 01/09/2018       1 Citation
  • Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation. (Narra RK, Flynn KE, Atallah E) Curr Hematol Malig Rep 2017 Oct;12(5):415-423 PMID: 28944397 PMCID: PMC6045428 SCOPUS ID: 2-s2.0-85029897925 09/26/2017       7 Citations
  • Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. (Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B) Am J Hematol 2017 Sep;92(9):E563-E565 PMID: 28631379 SCOPUS ID: 2-s2.0-85021972988 06/21/2017       4 Citations
  • Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. (Khoury HJ, Williams LA, Atallah E, Hehlmann R) Am Soc Clin Oncol Educ Book 2017;37:468-479 PMID: 28561719 SCOPUS ID: 2-s2.0-85041303313 06/01/2017       12 Citations
  • Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. (Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP) J Clin Oncol 2017 Aug 20;35(24):2745-2753 PMID: 28486043 PMCID: PMC5562170 SCOPUS ID: 2-s2.0-85028505702 05/10/2017       192 Citations
  • Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 SCOPUS ID: 2-s2.0-85019639994 04/17/2017       8 Citations
  • Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. (Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R Jr, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR, ONTIME study investigators) Lancet Oncol 2016 Apr;17(4):496-508 PMID: 26968357 SCOPUS ID: 2-s2.0-84959931622 03/13/2016       140 Citations
  • Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia. (Flynn KE, Atallah E) Curr Hematol Malig Rep 2016 Apr;11(2):80-5 PMID: 26879546 PMCID: PMC4860261 SCOPUS ID: 2-s2.0-84958241812 02/18/2016       37 Citations
  • A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. (Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H) Clin Lymphoma Myeloma Leuk 2016 Mar;16(3):139-45 PMID: 26775883 PMCID: PMC5557033 SCOPUS ID: 2-s2.0-84958922276 01/19/2016       56 Citations
  • Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. (Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC) Bone Marrow Transplant 2016 Apr;51(4):617-8 PMID: 26726940 SCOPUS ID: 2-s2.0-84953295752 01/05/2016       17 Citations
  • Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis. (Verstovsek S, Atallah E, Mascarenhas J, Sun H, Montgomery M, Gupta V, Mesa R, Gotlib J) Leukemia 2016 Jun;30(6):1413-5 PMID: 26526986 PMCID: PMC4895165 SCOPUS ID: 2-s2.0-84948424356 11/04/2015       6 Citations
  • Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. (Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN) Bone Marrow Transplant 2015 Jul;50(7):914-7 PMID: 25915809 SCOPUS ID: 2-s2.0-84934862607 04/29/2015       25 Citations
  • Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. (Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J) Clin Lymphoma Myeloma Leuk 2015 Apr;15(4):214-221.e1 PMID: 25682576 PMCID: PMC4418454 SCOPUS ID: 2-s2.0-84925412377 02/16/2015       61 Citations
  • Large granular lymphocytic leukemia presenting late after solid organ transplantation: a case series of four patients and review of the literature. (Kataria A, Cohen E, Saad E, Atallah E, Bresnahan B) Transplant Proc 2014 Dec;46(10):3278-81 PMID: 25240311 SCOPUS ID: 2-s2.0-84926339267 09/23/2014       6 Citations
  • Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. (Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, Yee K, Maganti M, Wong F, Gupta V) Clin Lymphoma Myeloma Leuk 2015 Jan;15(1):e1-5 PMID: 25027569 PMCID: PMC4361182 SCOPUS ID: 2-s2.0-84934440451 07/17/2014       22 Citations
  • Myelodysplastic syndromes in the United States: an update for clinicians. (Troy JD, Atallah E, Geyer JT, Saber W) Ann Med 2014 Aug;46(5):283-9 PMID: 24716735 SCOPUS ID: 2-s2.0-84905448514 04/11/2014       19 Citations
  • Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). (Atallah E, Bylow K, Troy J, Saber W) Curr Hematol Malig Rep 2014 Mar;9(1):57-65 PMID: 24398726 PMCID: PMC4031643 SCOPUS ID: 2-s2.0-84896710555 01/09/2014       12 Citations
  • Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. (Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA) Onco Targets Ther 2013;7:13-21 PMID: 24368888 PMCID: PMC3869911 SCOPUS ID: 2-s2.0-84890462687 12/26/2013       47 Citations
  • Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. (Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O) Clin Cancer Res 2014 Jan 15;20(2):490-8 PMID: 24178622 PMCID: PMC4310865 SCOPUS ID: 2-s2.0-84892716958 11/02/2013       96 Citations
  • Clarifying the use of ruxolitinib in patients with myelofibrosis. (Kremyanskaya M, Atallah EL, Hoffman R, Mascarenhas JO) Oncology (Williston Park) 2013 Jul;27(7):706-14 PMID: 23977767 SCOPUS ID: 2-s2.0-84880293714 08/28/2013       10 Citations
  • Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). (Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, Maziarz RT, Cortes J, Kalaycio ME, Horowitz MM) Blood 2013 Sep 12;122(11):1974-82 PMID: 23847196 PMCID: PMC3772501 SCOPUS ID: 2-s2.0-84887389178 07/13/2013       83 Citations
  • Emerging drugs for myelofibrosis. (Atallah E, Verstovsek S) Expert Opin Emerg Drugs 2012 Dec;17(4):555-70 PMID: 23186315 PMCID: PMC5009610 SCOPUS ID: 2-s2.0-84870443079 11/29/2012       5 Citations
  • Clinical regression of squamous cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent. (Randhawa J, Wong S, Atallah E, Olasz E) Int J Dermatol 2014 Jan;53(1):e13-4 PMID: 22998756 SCOPUS ID: 2-s2.0-84890794842 09/25/2012       2 Citations
  • Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. (Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S) J Hematol Oncol 2012 Aug 01;5:43 PMID: 22852872 PMCID: PMC3464878 SCOPUS ID: 2-s2.0-84864416539 08/03/2012       29 Citations
  • Myeloproliferative neoplasms. (Kim J, Haddad RY, Atallah E) Dis Mon 2012 Apr;58(4):177-94 PMID: 22449367 SCOPUS ID: 2-s2.0-84863382779 03/28/2012       9 Citations
  • Chronic myelogenous leukemia for primary care physicians. (Torgerson SR, Haddad RY, Atallah E) Dis Mon 2012 Apr;58(4):168-76 PMID: 22449366 SCOPUS ID: 2-s2.0-84858824580 03/28/2012       8 Citations
  • Nilotinib cardiac toxicity: should we still be concerned? (Atallah E) Leuk Res 2011 May;35(5):577-8 PMID: 21333353 SCOPUS ID: 2-s2.0-79954594715 02/22/2011       9 Citations
  • Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. (Atallah E, Abrams J, Ayash L, Bentley G, Abidi M, Ratanatharathorn V, Uberti J) Am J Hematol 2010 Aug;85(8):579-83 PMID: 20578198 PMCID: PMC3800118 SCOPUS ID: 2-s2.0-77955480515 06/26/2010       7 Citations
  • Recurrent deep vein thrombosis and pulmonary embolism in a young man with Klinefelter's syndrome and heterozygous mutation of MTHFR-677C>T and 1298A>C. (Angel JR, Parker S, Sells RE, Atallah E) Blood Coagul Fibrinolysis 2010 Jun;21(4):372-5 PMID: 20449891 SCOPUS ID: 2-s2.0-77951915862 05/08/2010       11 Citations
  • Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. (Bilgi N, Bell K, Ananthakrishnan AN, Atallah E) Ann Pharmacother 2010 May;44(5):926-8 PMID: 20332334 SCOPUS ID: 2-s2.0-77951554533 03/25/2010       95 Citations
  • Expression of natural killer receptors in T- and NK-cells: comparison of healthy individuals, patients with prior stem cell transplant, and patients undergoing chemotherapy. (Olteanu H, Schur BC, Bredeson C, Atallah E, Kroft SH) Leuk Lymphoma 2010 Mar;51(3):481-7 PMID: 20141431 SCOPUS ID: 2-s2.0-79954619318 02/10/2010       5 Citations
  • Resolution of rheumatoid arthritis symptoms with imatinib mesylate. (Vernon MR, Pearson L, Atallah E) J Clin Rheumatol 2009 Aug;15(5):267 PMID: 19654496 SCOPUS ID: 2-s2.0-69549097990 08/06/2009       10 Citations
  • Practical considerations for the management of patients in the tyrosine kinase inhibitor era. (O'Dwyer M, Atallah E) Semin Hematol 2009 Apr;46(2 Suppl 3):S16-21 PMID: 19621545 SCOPUS ID: 2-s2.0-63249106651 07/23/2009       12 Citations
  • Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. (Atallah E, Verstovsek S) Expert Rev Anticancer Ther 2009 May;9(5):663-70 PMID: 19445582 PMCID: PMC5176249 SCOPUS ID: 2-s2.0-68149160994 05/19/2009       27 Citations
  • Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. (Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, Atallah E) Leuk Res 2009 Aug;33(8):1144-6 PMID: 19394693 SCOPUS ID: 2-s2.0-67349165083 04/28/2009       32 Citations
  • Treatment strategies in myelodysplastic syndromes. (Atallah E, Garcia-Manero G) Cancer Invest 2008 Mar;26(2):208-16 PMID: 18259954 SCOPUS ID: 2-s2.0-38949120072 02/09/2008       10 Citations
  • Epigenetic Drugs: DNA Demethylating Agents (Atallah E, Garcia-Manero G) Epigenetics in Biology and Medicine 1 January 2008:27-48 SCOPUS ID: 2-s2.0-85123129158 01/01/2008    
  • Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. (Atallah E, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H, Verstovsek S) Leukemia 2008 Jun;22(6):1295-8 PMID: 18059483 SCOPUS ID: 2-s2.0-45149121653 12/07/2007       26 Citations
  • Use of hypomethylating agents in myelodysplastic syndromes. (Atallah E, Garcia-Manero G) Clin Adv Hematol Oncol 2007 Jul;5(7):544-52 PMID: 17679928 SCOPUS ID: 2-s2.0-34848895438 08/08/2007       6 Citations
  • Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. (Atallah E, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H) Blood 2007 Nov 15;110(10):3547-51 PMID: 17673605 SCOPUS ID: 2-s2.0-36348930556 08/04/2007       69 Citations
  • Congestive heart failure is a rare event in patients receiving imatinib therapy. (Atallah E, Durand JB, Kantarjian H, Cortes J) Blood 2007 Aug 15;110(4):1233-7 PMID: 17449798 SCOPUS ID: 2-s2.0-34548030470 04/24/2007       215 Citations
  • Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. (Atallah E, Kantarjian H, Cortes J) Clin Lymphoma Myeloma 2007 Mar;7 Suppl 3:S105-12 PMID: 17382019 SCOPUS ID: 2-s2.0-34249653546 03/27/2007       26 Citations
  • Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. (Atallah E, Cortes J) Curr Opin Hematol 2007 Mar;14(2):138-44 PMID: 17255791 SCOPUS ID: 2-s2.0-33846591021 01/27/2007       3 Citations
  • In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. (Atallah E, Kantarjian H, Cortes J) Nat Med 2007 Jan;13(1):14; author reply 15-6 PMID: 17206119 SCOPUS ID: 2-s2.0-33846086176 01/09/2007       37 Citations
  • The role of decitabine in the treatment of myelodysplastic syndromes. (Atallah E, Kantarjian H, Garcia-Manero G) Expert Opin Pharmacother 2007 Jan;8(1):65-73 PMID: 17163808 SCOPUS ID: 2-s2.0-33846078174 12/14/2006       27 Citations
  • Agent Orange, prostate cancer irradiation and acute promyelocyic leukemia (APL): is there a link? (Atallah E, Schiffer CA) Leuk Res 2007 May;31(5):720-1 PMID: 16956658 SCOPUS ID: 2-s2.0-34147180942 09/08/2006       2 Citations
  • Granulocyte transfusion. (Atallah E, Schiffer CA) Curr Opin Hematol 2006 Jan;13(1):45-9 PMID: 16319687 SCOPUS ID: 2-s2.0-33644848150 12/02/2005       37 Citations
  • Treatment of metastatic malignant melanoma. (Atallah E, Flaherty L) Curr Treat Options Oncol 2005 May;6(3):185-93 PMID: 15869730 SCOPUS ID: 2-s2.0-21744439869 05/05/2005       159 Citations
  • Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. (Atallah E, Talpaz M, O'brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H) Cancer 2002 Jun 01;94(11):2996-9 PMID: 12115389 SCOPUS ID: 2-s2.0-0036604263 07/13/2002       18 Citations
    • Last update: 04/17/2024